Neumora Therapeutics (NMRA) catalysts

Upcoming FDA decisions and readouts we track for Neumora Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 12 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Neumora Therapeutics (NMRA, listed on Nasdaq). They cover 2 programmes: NMRA-511 (Alzheimer’s disease agitation (V1a antagonist)) and NMRA-898 (Schizophrenia (M4 positive allosteric modulator)).

First on the list: the Phase 1 readout for NMRA-511 (Alzheimer’s disease agitation (V1a antagonist)), guided by the company to Q4 2026. By stage, the upcoming rows are 2 Phase 1 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: NMRA
Next catalyst: Q4 2026
Type: Phase 1 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Neumora Therapeutics NMRA · Nasdaq	NMRA-511	Alzheimer’s disease agitation (V1a antagonist)	Q4 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides data "from a MAD expansion cohort ... in the fourth quarter of 2026." Source: 8-K exhibit 99.1, filed 14 Aug 2026 · verified 12 Sep 2026
Neumora Therapeutics NMRA · Nasdaq	NMRA-898	Schizophrenia (M4 positive allosteric modulator)	H2 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states Neumora "expects to report data from the study in the second half of 2026." Source: 8-K exhibit 99.1, filed 14 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Annovis Bio (ANVS)Alzheimer’s disease — 6-month symptomatic data; Alzheimer’s disease — disease-modifying data
LB Pharmaceuticals (LBRX)Schizophrenia; Bipolar depression
MapLight Therapeutics (MPLT)Alzheimer’s disease psychosis (hallucinations and delusions)
Minerva Neurosciences (NERV)Negative symptoms of schizophrenia
Rapport Therapeutics (RAPP)Bipolar mania (AMPA receptor modulator); Focal onset seizures — open-label safety; Neurological disorders (LAI formulation)

Also due in Q4 2026

MacroGenics (MGNX)Phase 1 readout for MGC026, Oct 2026
Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026
Arvinas (ARVN)Phase 1 readout for ARV-102, Oct 2026
Xencor (XNCR)Phase 1 readout for XmAb819, Oct 2026
MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026
Aprea Therapeutics (APRE)Phase 1 readout for APR-1051, Q4 2026